PDE4D: IHC Expression in Cancer and Radioligand Target Profile
PDE4D, phosphodiesterase 4D, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PDE4D staining is highest in colorectal cancer (100% of samples positive), melanoma (100% of samples positive) and prostate cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).
Is PDE4D the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze PDE4D freeIs PDE4D a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in colorectal cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PDE4D IHC staining by cancer type
Protein expression of PDE4D across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Colorectal Cancer | 0.94 | High | 100% |
| Melanoma | 0.93 | High | 100% |
| Prostate Cancer | 0.89 | High | 100% |
| Endometrial Cancer | 0.88 | High | 100% |
| Lung Cancer | 0.81 | High | 100% |
| Neuroendocrine Tumors | 0.75 | High | 100% |
| Breast Cancer | 0.74 | High | 100% |
| Bladder Cancer | 0.70 | High | 100% |
| Ovarian Cancer | 0.69 | High | 100% |
| Cervical Cancer | 0.69 | High | 100% |
| Gastric Cancer | 0.69 | High | 100% |
| Liver Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Kidney Cancer | 0.67 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Pancreatic Cancer | 0.64 | High | 92% |
| Lymphoma | 0.58 | High | 100% |
| Glioma | 0.57 | High | 100% |
| Skin Cancer | 0.52 | High | 91% |
| Testicular Cancer | 0.46 | Medium | 100% |
Is PDE4D internalized?
Nuclens has not yet extracted internalization evidence for PDE4D. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
PDE4D clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for PDE4D yet. Search ClinicalTrials.gov for PDE4D trials.
PDE4D normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PDE4D in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PDE4D gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related colorectal cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EGFR · FAP · CEA (CEACAM5) · EPCAM · SSTR2 · STEAP2
See all radioligand therapy targets in colorectal cancer.
See how PDE4D ranks against 15,000 targets for your indication.
Analyze PDE4D freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.